FDA Approves MACRILEN — Aeterna Zentaris GmbH
On December 20, 2017, the FDA approved macimorelin (Macrilen), developed by Aeterna Zentaris GmbH, marking a significant milestone as the first endogenous ghrelin mimetic treatment for adult growth hormone deficiency. This oral drug approval opens a new therapeutic category with substantial market implications, potentially shifting prescribing trends within the competitive somatropin landscape.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day